All In Biotech

Drug Trial Radar · NCT07503756

JS212 Combination Therapies in Metastatic Colorectal Cancer

An Open-label, Multicenter Phase 2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of JS212 Combination Therapies in Patients With Metastatic Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Apr 25, 2026

Primary completion

Dec 30, 2027

Study completion Mar 30, 2028

Sponsor

Lead sponsor
Shanghai Junshi Bioscience Co., Ltd.Academic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 31, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter Phase 2 clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of JS212-based combination therapies in patients with metastatic colorectal cancer (mCRC). JS212 is a bispecific antibody-drug conjugate (ADC) targeting epidermal growth factor receptor (EGFR) and HER3 with a topoisomerase I inhibitor payload. Preclinical and early clinical data suggest that dual targeting of EGFR and HER3 may enhance antitumor activity and overcome resistance mechanisms associated with EGFR- or HER2-directed therapies. This study will investigate JS212 in combination with capecitabine, with or without Bevacizumab, and JS212 in combination with chemotherapy (XELOX: capecitabine and oxaliplatin), with or without the PD-1/VEGF bispecific antibody JS207, in patients with mCRC. The study will assess safety, determine the recommended Phase 3 dose (RP3D), and evaluate preliminary antitumor activity of the combination regimens.

Conditions

  • Metastatic Colorectal Cancer

Interventions

  • JS212Drug

    Bispecific antibody-drug conjugate targeting EGFR and HER3

  • CapecitabineDrug

    Oral fluoropyrimidine chemotherapy

  • BevacizumabDrug

    Humanized anti-VEGF monoclonal antibody

  • OxaliplatinDrug

    Platinum-based chemotherapy administered intravenously

  • JS207Drug

    Bispecific antibody targeting PD-1 and VEGF

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Investigator-assessed objective response rate (ORR)Time frame: Up to approximately 12 months
  2. Safety and Tolerability(AEs)Time frame: From first dose up to approximately 90 days after last dose
  3. Safety and Tolerability(SAEs)Time frame: From first dose up to approximately 90 days after last dose
  4. Safety and Tolerability(DLTs)Time frame: From first dose up to approximately 90 days after last dose
  5. Maximum Tolerated Dose (MTD)Time frame: Up to approximately 6 months
  6. Recommended Phase 3 Dose (RP3D)Time frame: Up to approximately 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.